access pharma logo Access Pharmaceuticals

  • About Us
    • Board of Directors
    • Senior Management
  • Product Programs
    • MuGard
      • Fact Sheet
      • MuGard.com
      • Order Form
    • ProLindac
      • Chemistry
      • Preclinical data
      • Future Development
    • Cobalamin mediated oral drug delivery
    • Thiarabine
    • CobaCyte - Cobalamin targeted delivery
    • Publications
  • Business Development
  • Investor Relations
  • Newsroom
    • 2011
    • 2010
    • 2009
  • Contact Us
flash placeholder

Product Programs

  • MuGard
  • ProLindac
  • Cobalamin mediated oral drug delivery
  • Thiarabine
  • CobaCyte - Cobalamin targeted delivery
  • Publications

 

Contact

  • 2600 Stemmons Freeway,
  • Suite 176
  • Dallas, TX 75207-2107
  • Tel: (214) 905-5100
  • Fax: (214) 905-5101
info@accesspharma.com

Sign up for news alerts!

Product Pipeline

  • Sign up for news alerts!

  • Latest Product Programs News & Events

    • 12.07.11
      MUGARD ADVOCATE INTERVIEWED ON ABC TAMPA NEWS AT NOON
    • 11.15.11
      Access Pharmaceuticals Provides Third Quarter Update on MuGard Commercial Activities
    • 10.14.11
      Access Pharmaceuticals Updates MuGard Website with New Video Featuring Clinical Feedback and Manufacturing Footage
    • 10.13.11
      Access Pharmaceuticals Provides Update on Increasing Payer Uptake for MuGard
    • 09.28.11
      Access Pharmaceuticals Reports Additional MuGard Study Findings Presented at EMCC 2011 in Stockholm
    More News
© Access Pharmaceuticals 2009 | Disclaimer